Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FL115 and Sintilimab in Advanced Solid Tumors
NCT07131202Phase 2Recruiting
- Sponsor
- Forlong Biotechnology
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FL-115 in solid tumor (advanced stage), sponsored by Forlong Biotechnology. Primary endpoints: Safety and Tolerance, Maximum Tolerated Dose and Recommended Dose for Expansion at 15 months and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
FL-115
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07131202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131202.